Drug coverage for seniors is better addressed by private-sector plans than by forcing manufacturers to offer Federal Supply Schedule discounts to the retail sector.

The authors demonstrate how regulation intended to control costs can exacerbate cost growth by subsidizing high-risk activities and firms at the expense of low-risk activities and firms.

The author examines the effect of existing foreign regulation on U.S. firms, the major producers of innovative drugs.

This book discusses how global budgets relate to competitive cost-control strategies.

Are drug prices in the United States higher than in other countries? The answer to this question is not as simple as it may seem. Patricia Danzon and her colleagues at the University of Pennsylvania's Wharton School have recently published three articles that explore the complex issues involved in making...

Many people expect the Congress to turn to a serious discussion of how to design a prescription drug benefit for Medicare following the election in November. Many questions remain about how Medicare would purchase prescription drugs and make them conveniently available in each local area. Should Medicare select local...

Pharmaceutical price controls have become a controversial political issue. Numerous federal and state legislators have proposed reducing pharmaceutical prices by various methods. President Clinton's proposed out-patient drug benefit for Medicare-with special mechanisms for negotiating drug prices--is expected to be one of the high-visibility legislative proposals Congress considers in this election...